Q3 Earnings Estimate for Imunon Issued By Zacks Research

Imunon, Inc. (NASDAQ:IMNN) – Analysts at Zacks Research issued their Q3 2026 EPS estimates for shares of Imunon in a research report issued on Thursday, May 14th. Zacks Research analyst D. Bautz expects that the company will post earnings of ($0.87) per share for the quarter. The consensus estimate for Imunon’s current full-year earnings is ($3.44) per share. Zacks Research also issued estimates for Imunon’s Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($1.84) EPS.

Imunon (NASDAQ:IMNN) last announced its earnings results on Tuesday, May 12th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.38.

A number of other equities analysts have also recently commented on IMNN. Maxim Group set a $10.00 target price on shares of Imunon and gave the company a “buy” rating in a report on Friday, April 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $10.00.

Imunon Price Performance

Shares of Imunon stock opened at $2.26 on Tuesday. The firm’s fifty day simple moving average is $2.92 and its 200-day simple moving average is $3.41. The stock has a market capitalization of $9.50 million, a price-to-earnings ratio of -0.44 and a beta of 2.04. Imunon has a 12 month low of $2.22 and a 12 month high of $41.22.

Hedge Funds Weigh In On Imunon

Hedge funds and other institutional investors have recently bought and sold shares of the company. Armistice Capital LLC purchased a new position in Imunon in the 4th quarter valued at $1,017,000. DRW Securities LLC grew its position in Imunon by 6.9% in the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock valued at $224,000 after buying an additional 3,803 shares during the last quarter. Finally, Riverview Capital Advisers LLC grew its position in Imunon by 193.3% in the 3rd quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock valued at $176,000 after buying an additional 22,649 shares during the last quarter. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.